observ
data
suggest
treatment
infl
uenza
infect
neuraminidas
inhibitor
decreas
progress
sever
ill
especi
treatment
start
soon
symptom
onset
howev
even
earli
treatment
might
fail
prevent
complic
patient
particularli
infect
novel
virus
pandem
infl
uenza
avian
infl
uenza
viru
subtyp
avian
infl
uenza
viru
subtyp
furthermor
treatment
one
antivir
drug
might
promot
develop
antivir
resist
especi
immunocompromis
host
critic
ill
patient
obviou
strategi
optimis
antivir
therapi
combin
drug
diff
erent
mode
action
host
immun
respons
infect
might
also
contribut
ill
pathogenesi
improv
outcom
might
gain
combin
antivir
therapi
drug
modul
immun
respons
infect
individu
review
avail
data
preclin
clinic
studi
combin
antivir
therapi
combin
antiviralimmunomodul
therapi
infl
uenza
earlystag
data
draw
attent
sever
promis
antivir
combin
therapeut
potenti
sever
infect
remain
need
substanti
clinic
benefi
combin
therapi
favour
experiment
data
need
test
care
design
aclin
trial
assess
effi
caci
infl
uenza
viru
infect
caus
substanti
morbid
mortal
despit
avail
antivir
drug
vaccin
estim
annual
epidem
caus
million
million
case
sever
ill
death
worldwid
pandem
outbreak
strain
continu
caus
seriou
ill
increas
mortal
particularli
young
adult
children
increas
zoonot
infect
avian
infl
uenza
virus
also
concern
second
wave
avian
infl
uenza
occur
china
late
earli
high
rate
sever
ill
death
patient
confi
rmed
infect
viru
continu
circul
poultri
fi
rst
time
sever
avian
infl
uenza
infect
human
be
describ
case
avian
infl
uenza
continu
report
includ
fi
rst
case
import
infect
north
america
variou
observ
studi
season
pandem
avian
infl
uenza
infect
show
time
oseltamivir
monotherapi
reduc
risk
sever
infl
uenza
outcom
pneumonia
admiss
hospit
lower
mortal
hospit
inpati
includ
risk
group
pregnant
women
immuno
compromis
host
howev
monotherapi
prevent
death
mani
patient
sever
pandem
ill
although
variou
factor
might
account
death
oseltamivir
treatment
associ
incomplet
antivir
respons
sever
ill
patient
viral
detect
persist
upper
often
lower
respiratori
tract
day
sometim
week
otreat
furthermor
emerg
resist
monotherapi
drawback
sever
infl
uenza
particularli
immuno
compromis
host
avian
infect
variant
highli
reduc
inhibit
oseltamivir
vitro
sometim
emerg
within
sever
day
initi
therapi
sever
infl
uenza
caus
pandem
avian
virus
model
studi
base
human
viral
kinet
show
possibl
singl
nucleotid
mutat
sizeabl
proport
doubl
one
gener
uncompl
infl
uenza
infect
wherea
mutat
sustain
fi
tness
cost
variant
show
reduc
inhibit
select
drug
therapi
therapeut
use
infl
uenza
antivir
combin
could
increas
antivir
potenc
reduc
resist
emerg
eff
ect
could
increas
clinic
eff
ectiv
especi
serious
ill
immunocompromis
host
addit
combin
might
allow
dosespar
event
drug
shortag
possibl
reduc
risk
advers
drug
eff
ect
broad
rang
respons
infect
seen
high
rate
clinic
inappar
infect
report
seroepidemiolog
studi
show
sever
infl
uenza
least
part
determin
host
factor
death
mani
case
result
irrevers
lung
injuri
relat
host
infl
ammatori
respons
direct
cellular
eff
ect
viral
infect
cytopatholog
apoptosi
henc
modul
host
proinfl
ammatori
respons
might
tractabl
complementari
therapeut
strategi
er
advantag
compar
antivir
avoid
emerg
drugresist
variant
furthermor
hostcel
pathway
essenti
viral
replic
hostdirect
inhibitor
potenti
diminish
viral
replic
harm
infl
ammatori
respons
well
establish
therapeut
approach
antivir
combin
receiv
limit
clinic
test
infl
uenza
infect
far
littl
inform
avail
studi
hospitalis
sever
ill
patient
infl
uenza
consequ
combin
proven
valu
treatment
sever
human
infl
uenza
avail
review
summaris
publish
inform
regard
infl
uenza
antivir
combin
review
comment
antivir
immunomodul
combin
ation
receiv
preclin
instanc
clinic
investig
detail
repres
studi
antivir
combin
antivir
immunomodul
combin
list
appendix
sever
regimen
would
candid
control
studi
hospit
inpati
seriou
infl
uenza
infect
includ
patient
infect
avian
infl
uenza
viru
patient
immunocompromis
increas
risk
sever
diseas
resist
emerg
previous
review
invitro
studi
show
enhanc
antivir
activ
infl
uenza
viru
dual
drug
regimen
amantadin
interferon
date
ofrimantadin
ribavirin
date
combin
amantadin
ribavirin
report
increas
surviv
murin
model
infl
uenza
viru
infect
although
infl
uenza
b
reduct
adamantan
resist
emerg
vitro
combin
rimantadin
ribavirin
report
principl
subsequ
support
amantadin
oseltamivir
mani
infl
uenza
subtyp
includ
avian
fi
rst
tripl
infl
uenza
drug
regimen
interferon
alfa
rimantadin
ribavirin
show
enhanc
invitro
activ
infl
uenza
describ
investig
also
note
enhanc
activ
combin
ribavirin
interferon
alfa
infl
uenza
b
viru
neuraminidas
inhibitor
becam
avail
preclin
studi
show
addit
synergist
invitro
activ
increas
surviv
murin
model
combin
adamantan
neuraminidas
inhibitor
fi
rst
randomis
control
trial
combin
therapi
hospit
inpati
done
collabor
antivir
studi
group
late
show
regimen
oral
rimantadin
nebulis
zanamivir
seem
exert
slightli
greater
antivir
eff
ect
prevent
emerg
adamantan
resist
compar
one
rimantadin
nebulis
salin
subsequ
randomis
control
trial
outpati
report
evid
possibl
antagon
combin
oral
oseltamivir
inhal
zanamivir
observ
emphasis
import
detail
preclin
studi
embark
clinic
trial
subsequ
studi
led
sever
randomis
control
trial
test
safeti
effi
caci
variou
combin
infl
uenza
antivir
tabl
present
circul
infl
uenza
virus
includ
avian
infl
uenza
suscept
neuraminidas
inhibitor
ovesrv
clinic
data
show
reduc
mortal
time
oseltamivir
therapi
diseas
preclin
studi
show
least
addit
often
synergist
interact
neuraminidas
inhibitor
antivir
drug
diff
erent
mechan
action
consequ
oseltamivir
avail
intraven
zanamivir
peramivir
would
logic
choic
use
foundat
drug
test
antivir
combin
sever
issu
emerg
possibl
dual
neuraminidas
inhibitor
therapi
consid
use
dual
neuraminidas
inhibitor
combin
might
er
possibl
reduc
resist
emerg
diff
ere
antivir
resist
profi
le
among
drug
howev
data
substanti
potenti
advantag
combin
oseltamivir
zanamivir
peramivir
show
concentrationdepend
addit
antagonist
antivir
eff
ect
virus
vitro
wherea
anoth
studi
report
combin
oseltamivir
peramivir
show
mainli
addit
activ
vitro
mice
review
similar
chemic
structur
oseltamivir
peramivir
either
instanc
greater
antivir
eff
ect
potent
drug
two
would
expect
infl
uenza
neuraminidas
form
two
group
phylogenet
analysi
group
group
group
distinct
structur
featur
includ
protein
loop
open
activesit
conform
group
neuraminidas
close
activesit
conform
group
neuraminidas
although
oseltamivir
zanamivir
inhibit
group
similar
degre
oseltamivirresist
virus
show
neuraminidas
group
specifi
citi
mediat
specifi
c
aminoacid
chang
aminoacid
substitut
select
vitro
oseltamivir
includ
sever
also
seen
virus
patient
given
oseltamivir
eg
number
although
catalyt
site
substitut
caus
mark
fi
tness
loss
also
confer
highli
reduc
inhibit
oseltamivir
reduct
enzym
inhibit
assay
reduc
inhibit
zanamivir
greater
extent
peramivir
substitut
number
also
caus
highli
reduc
inhibit
oseltamivir
peramivir
reduc
inhibit
zanamivir
avian
infl
uenza
vitro
absenc
inhibit
mice
given
neuraminidas
inhibitor
note
emerg
substitut
report
earli
day
initi
oseltamivir
patient
infect
associ
poor
clinic
outcom
variant
replic
least
well
madindarbi
canin
cell
primari
human
respiratori
cell
suscept
viru
show
similar
virul
mice
transmiss
guineapig
fi
nding
show
fi
tness
eff
ect
background
much
less
report
virus
substitut
might
render
avail
neuraminidas
inhibitor
clinic
ineff
ectiv
healthi
volunt
combin
administr
intraven
zanamivir
oral
oseltamivir
intra
venou
peramivir
oral
oseltamivir
show
import
pharmacokinet
interact
one
randomis
doubleblind
placebocontrol
trial
identifi
ed
slower
virolog
clinic
respons
patient
given
combin
therapi
oseltamivir
inhal
zanamivir
compar
oseltamivir
alon
treatment
uncompl
mostli
infl
uenza
adult
although
combin
might
eff
ectiv
reduc
secondari
transmiss
small
randomis
control
trial
outpati
infect
pandem
viru
show
obviou
diff
erenc
antivir
eff
ect
combin
compar
oseltamivir
alon
howev
observ
studi
oseltamivirpretr
sever
ill
patient
pandem
viru
show
late
switch
intraven
zanamivir
associ
sustain
viralload
reduct
three
three
patient
given
zanamivir
monotherapi
three
ten
given
combin
therapi
oseltamivir
anoth
openlabel
trial
critic
ill
patient
pandem
viru
report
persist
viral
detect
still
rna
posit
infl
uenza
day
start
treatment
despit
administr
combin
higher
dose
oral
oseltamivir
inhal
zanamivir
consequ
result
rais
concern
advers
interact
combin
zanamivir
oseltamivir
preclin
assess
includ
enzym
inhibit
studi
warrant
use
clinic
practic
circul
threaten
infl
uenza
virus
present
adamantaneresist
includ
avian
pandem
avian
season
virus
howev
adamantan
resist
variabl
avian
virus
mani
isol
suscept
preclin
studi
adamantanesuscept
infl
uenza
viru
combin
use
adamantan
neuraminidas
inhibitor
ribavirin
gener
show
addit
synergist
interact
vitro
increas
surviv
murin
model
infl
uenza
includ
avian
viru
howev
infl
uenza
viru
adamantaneresist
addit
surviv
benefi
antivir
eff
ect
shown
adamantan
also
given
compar
oseltamivir
ribavirin
monotherapi
although
one
studi
report
increas
surviv
dual
combin
amantadin
oseltamivir
ribavirin
adamantaneresist
pandem
viru
mice
human
studi
combin
oral
oseltamivir
amantadin
oral
rimantadin
intraven
peramivir
shown
import
pharmacokinet
interact
one
placebocontrol
underpow
trial
nebulis
zanamivir
patient
infl
uenza
admit
hospit
given
rimantadin
show
trend
toward
faster
cough
resolut
lesser
risk
adamantan
resist
emerg
consequ
dual
regimen
adamantan
neuraminidas
inhibitor
would
reason
initi
treatment
regimen
seriou
infl
uenza
infect
strain
probabl
suscept
drug
class
combin
ribavirin
neuraminidas
inhibitor
shown
variabl
interact
peramivir
ribavirin
show
synergist
activ
viru
vitro
enhanc
surviv
eff
ect
given
oral
combin
compar
suboptimum
dose
either
agent
sever
oseltamivir
ribavirin
dose
combin
increas
surviv
reduc
lung
consolid
review
reduc
lung
viral
titr
infl
uenza
b
compar
suboptimum
dose
singl
agent
wherea
one
dose
regimen
oseltamivir
ribavirin
show
greater
eff
ect
ribavirin
alon
mice
inject
anew
ribavirin
oseltamivir
shown
mainli
addit
interact
preclin
assay
mice
infect
avian
viru
oseltamivir
ribavirin
also
show
except
margin
synergi
slight
antagon
dose
combin
uncompl
season
infl
uenza
randomis
control
trial
show
ribavirin
monotherapi
ineff
ectiv
dose
g
per
day
margin
benefi
ts
clinic
manifest
higher
dose
g
given
day
aerosolis
intraven
ribavirin
prepar
use
possibl
benefi
sever
ill
patient
infl
uenza
combin
oral
ribavirin
amantadin
use
treatment
infl
uenza
pneumonia
pregnant
patient
surviv
howev
assess
us
food
drug
administr
expert
conclud
data
compassion
use
report
intraven
ribavirin
infl
uenza
inconclus
term
clinic
benefi
ts
also
point
potenti
safeti
issu
associ
ribavirin
haemolyt
anaemia
teratogenioc
tcad
regimen
adama
emeryvil
ca
usa
three
avail
agent
amantadin
ribavirin
oseltamivir
show
synergist
activ
vitro
infl
uenza
virus
suscept
also
resist
adamantan
oseltamivir
baselin
includ
adamantaneresist
pandem
viru
tcad
inhibitori
dual
combin
also
eff
ectiv
prevent
resist
emerg
invitro
passag
murin
model
studi
report
greater
surviv
dual
combin
adamantanesuscept
viru
also
adamantaneresist
pandem
viru
howev
virolog
data
provid
establish
whether
improv
surviv
associ
greater
antivir
eff
ect
possibl
reduc
resist
emerg
vivo
small
cohort
highli
immunocompromis
patient
infect
infl
uenza
tcad
recipi
emerg
resistanceassoci
substitut
regimen
reason
well
toler
day
provid
target
blood
concentr
individu
drug
retrospect
observ
studi
critic
ill
adult
infect
pandem
viru
suggest
nonsignifi
cant
trend
toward
reduc
day
vs
day
vs
mortal
tcad
recipi
compar
receiv
oseltamivir
monotherapi
randomis
control
trial
trial
sponsor
nation
institut
allergi
infecti
diseas
compar
tcad
oseltamivir
monotherapi
ambulatori
highrisk
patient
progress
control
studi
hospit
inpati
seem
warrant
favipiravir
toyama
chemic
co
tokyo
japan
novel
infl
uenza
polymeras
inhibitor
activ
infl
uenza
b
c
virus
includ
adamantaneresist
oseltamivirresist
variant
favipiravir
oseltamivir
show
concentrationrel
addit
synergist
eff
ect
infl
uenza
virus
vitro
depend
dose
time
surviv
mice
infect
variou
infl
uenza
virus
combin
suboptimum
dose
favipiravir
oseltamivir
aff
ord
protect
improv
bodyweight
infect
lethal
model
one
design
give
infecti
dose
predict
associ
mortal
combin
favipiravir
peramivir
also
show
synergi
surviv
enhanc
antivir
eff
ect
compar
suboptimum
dose
compound
alon
treatment
pandem
viru
mice
limit
test
record
pharmacokinet
interact
oral
favipiravir
oseltamivir
healthi
particip
howev
dose
adjust
set
renal
insuffi
cienci
still
identifi
ed
recommend
dose
regimen
vari
target
popul
asian
white
japan
favipiravir
approv
treatment
novel
reemerg
infl
uenza
viru
infect
limit
case
antiinfl
uenza
viru
drug
ineff
ectiv
suffi
cientli
eff
ectiv
phase
studi
uncompl
infl
uenza
show
similar
antivir
eff
ect
oseltamivir
phase
treatment
studi
complet
adult
report
evid
symptom
allevi
larg
phase
randomis
control
trial
uncompl
diseas
initi
season
view
avail
preclin
data
oral
favipiravir
would
especi
interest
candid
studi
combin
therapi
neuraminidas
inhibitor
seriou
infl
uenza
viral
infect
plasma
contain
virusspecifi
c
neutralis
antibodi
use
appar
benefi
neuraminidas
inhibitortr
patient
sever
infect
cohort
studi
neuraminidas
inhibitortr
critic
ill
patient
infect
pandem
viru
crude
mortal
reduc
nontreat
patient
patient
receiv
convalesc
plasma
substanti
reduct
nasopharyng
viral
load
quantiti
viral
rna
copi
number
volum
sampl
treatment
day
plasma
cytokin
chemokin
record
compar
control
similar
critic
ill
group
patient
receiv
neuraminidas
inhibitor
therapi
small
doubleblind
review
randomis
control
trial
hyperimmun
globulin
contain
high
neutralis
antibodi
titr
infl
uenza
pandem
viru
associ
mortal
treatment
given
within
day
ill
onset
compar
receiv
intraven
immunoglobulin
although
overal
mortal
diff
er
group
delay
administr
includ
fi
treat
four
untreat
fi
nding
suggest
combin
neuraminidas
inhibitor
therapi
neutralis
antibodi
form
convalesc
plasma
hyperimmun
globin
would
appropri
choic
studi
patient
sever
ill
avail
broadspectrum
neutralis
monoclon
antibodi
target
conserv
epitop
stem
viral
haemagglutinin
inhibit
fusion
therapeut
activ
anim
model
infl
uenza
group
haemagglutinin
includ
group
haemagglutinin
includ
group
haemagglutinin
one
paninfl
uenza
anti
haemag
glutinin
stem
monoclon
antibodi
design
increas
surviv
mice
infect
viru
combin
oseltamivir
compar
either
singl
agent
antibodi
enter
clinic
trial
present
might
er
broadspectrum
activ
especi
possess
suffi
cient
avid
deliv
suffi
cient
quantiti
sever
antivir
possess
novel
mechan
action
show
antiinfl
uenza
activ
initi
clinic
studi
would
also
option
potenti
combin
regimen
neuraminidas
inhibitor
approv
drug
nitazoxanid
approv
oral
antiparasit
agent
well
defi
ned
safeti
profi
le
human
pharma
colog
vitro
nitazoxanid
activ
metabolit
tizoxanid
inhibit
infl
uenza
viru
replic
submicromolar
concentr
nitazoxanid
reportedli
interferon
induc
inhibitor
infl
uenza
antihaemagglutinin
matur
novel
mechan
action
scarc
invitro
test
show
evid
synergi
combin
tizoxanid
neuraminidas
inhibitor
preclin
test
placebocontrol
phase
randomis
control
trial
uncompl
infl
uenza
show
great
antivir
eff
ect
clinic
benefi
roughli
h
reduct
ill
durat
dose
mg
twice
day
compar
placebo
sponsorship
biomed
advanc
research
develop
author
barda
larg
phase
randomis
placebocontrol
trial
initi
compar
nitazoxanid
mono
therapi
oseltamivir
monotherapi
combin
oseltamivir
nitazoxanid
treatment
uncompl
infl
uenza
inhal
ansun
biopharma
san
diego
ca
usa
conjug
sialidas
destroy
sialic
acidbear
receptor
host
cell
use
infl
uenza
b
parainfl
uenza
virus
initi
infect
topic
appli
activ
murin
ferret
model
infl
uenza
includ
infl
uenza
virus
novel
hostdirect
mechan
action
activ
virus
resist
exist
agent
low
risk
resist
emerg
longlast
invitro
passag
infl
uenza
virus
presenc
lead
emerg
unstabl
variant
three
reduct
suscept
contain
substitut
antihaemagglutinin
neuroaminidas
inhal
show
great
antivir
eff
ect
phase
randomis
control
trial
uncompl
infl
uenza
although
demonstr
eff
ect
ill
resolut
inhal
rout
might
prove
diffi
cult
sever
ill
sever
case
report
shown
appar
clinic
benefi
seriou
advers
event
use
treatment
seriou
parainfl
uenza
viru
immunocompromis
host
studi
uncompl
infl
uenza
progress
arbidol
oral
antivir
avail
use
infl
uenza
treatment
russia
avail
overthecount
sinc
countri
broad
spectrum
inhibitori
eff
ect
mani
envelop
rna
virus
also
specifi
calli
target
infl
uenza
antihaemagglutininmedi
membran
fusion
arbidolresist
variant
select
vitro
substitut
antihaemagglutinin
subunit
arbidol
show
doserel
antivir
eff
ect
surviv
murin
model
studi
experi
cell
cultur
shown
synergist
eff
ect
combin
adamantan
ribavirin
neuraminidas
inhibitor
randomis
control
trial
data
clinic
antivir
effi
caci
avail
seem
gener
well
toler
use
infl
uenza
prophylaxi
treatment
russian
studi
studi
progress
arbidol
would
interest
candid
combin
studi
particularli
countri
alreadi
use
monotherapi
oral
vertex
pharmaceut
boston
usa
novel
mechan
action
select
infl
uenza
virus
activ
neuraminidaseinhibitor
variant
adamantaneresist
variant
would
probabl
show
enhanc
activ
combin
neuroaminidas
inhibitor
oral
report
posit
antivir
clinic
eff
ect
phase
experiment
infect
studi
human
be
highest
dose
test
mg
follow
mg
daili
day
serepta
cambridg
smallinterf
rna
sirna
construct
design
inhibit
translat
matrix
protein
ion
channel
target
share
translat
initi
start
site
modifi
ed
phosphorodiamid
review
morpholino
oligom
enhanc
resist
enzymat
degrad
improv
pharmacolog
properti
limit
potenti
nonspecifi
c
immuno
modulatori
eff
ect
ferret
studi
oseltamivirresist
viru
shown
diseas
moder
reduc
viral
titr
topic
intraperiton
administr
includ
reduc
transmiss
ferret
intranas
administr
although
oseltamivir
inhibitori
model
combin
intranas
intraperiton
oral
oseltamivir
tend
reduc
nasal
viral
titr
greater
extent
alon
nation
institut
allergi
infecti
diseas
conduct
phase
randomis
placebocontrol
trial
assess
safeti
toler
pharmacokinet
singl
multipl
dose
intraven
healthi
particip
sever
potenti
immunomodulatori
agent
propos
adjunct
infl
uenza
treatment
mainli
direct
excess
proinfl
ammatori
host
respons
infect
mani
shown
activ
anim
model
new
candid
agonist
human
complement
compon
term
retino
acidinduc
gene
rigi
agonist
rna
tolllik
receptor
antagonist
eritoran
eisaico
tokyo
japan
continu
report
exampl
studi
suggest
endogen
lipid
mediat
protectin
downregul
sever
infl
uenza
exogen
administr
exert
antivir
eff
ect
improv
outcom
sever
infl
uenza
mous
model
agent
dual
mechan
action
also
describ
cyclooxygenas
inhibitor
naproxen
shown
inhibit
infl
uenza
nucleoprotein
exert
antivir
eff
ect
murin
model
depend
particular
model
drug
either
proinfl
ammatori
antiinfl
ammatori
eff
ect
shown
benefi
ts
anim
model
howev
immunomodul
studi
combin
infl
uenza
antivir
preclin
studi
none
studi
adequ
power
randomis
control
trial
seriou
human
infl
uenza
appendix
furthermor
unclear
relat
diseas
pathogenesi
anim
model
especi
murin
one
human
infl
uenza
heterogen
factor
contribut
sever
human
infl
uenza
mean
predict
valu
immunomodul
activ
anim
model
infl
uenza
studi
unclear
one
obviou
concern
downregul
import
innat
immun
respons
could
contribut
inadequ
control
viral
replic
associ
worsen
clinic
outcom
howev
immunomodulatori
agent
mammalian
target
rapamycin
mtor
inhibitor
inhibitor
rafmekerk
pathway
seem
target
host
cell
pathway
essenti
viral
replic
mtor
inhibitor
everolimu
show
antivir
eff
ect
diseas
mitig
lethal
murin
model
infl
uenza
small
openlabel
randomis
control
trial
critic
ill
adult
infect
pandem
viru
pjp
given
oral
oseltamivir
system
corticosteroid
show
rapid
improv
respiratori
function
shown
paramet
ga
exchang
need
mechan
ventil
reduc
viral
detect
day
recipi
mtor
inhibitor
sirolimu
compar
treatment
although
overal
diff
erenc
mortal
potenti
valu
mtor
inhibitor
sever
infl
uenza
warrant
studi
immunomodulatori
agent
increas
surviv
combin
infl
uenza
antivir
murin
model
includ
nacetylcystein
topic
sphingosin
analogu
design
aalr
inhibit
variou
proinfl
ammatori
cytokin
chemokin
respons
inhibitor
celecoxib
mesalazin
thymosin
topic
surfact
probenecid
addit
enhanc
antivir
activ
report
combin
probenecid
oseltamivir
treatment
mous
model
infl
uenza
combin
particularli
interest
sinc
probenecid
inhibit
oseltamivir
carboxyl
excret
potenti
enabl
either
boost
blood
concentr
dosingspar
use
wide
avail
low
cost
drug
immunomodulatori
activ
promot
possibl
treatment
strategi
far
prospect
randomis
control
trial
agent
complet
patient
sever
infl
uenza
ill
mice
infect
avian
viru
simvastatin
given
oseltamivir
improv
effi
caci
oseltamivir
monotherapi
wherea
preliminari
studi
report
diseasemodifi
eff
ect
tripl
regimen
osetltamivir
simvastatin
fenofi
brate
compar
oseltamivir
alon
observ
studi
pandem
fi
nd
improv
outcom
sever
ill
patient
given
neuraminidas
inhibitor
variou
immunomodulatori
therapi
includ
macrolid
statin
one
retrospect
analysi
uncompl
infl
uenza
fi
nd
addit
clarithromycin
oseltamivir
improv
clinic
outcom
prospect
observ
studi
critic
ill
patient
infl
uenza
without
evid
bacteri
coinfect
treatment
macrolid
associ
improv
surviv
howev
sever
retrospect
studi
report
substanti
mortal
benefi
ts
patient
take
statin
subsequ
admit
hospit
season
infl
uenza
pneumonia
studi
shown
result
possibl
benefi
start
statin
time
infl
uenza
onset
treatment
review
hospit
report
one
randomis
control
trial
intens
care
unit
suggest
reduc
risk
ventilatorassoci
pneumonia
mortal
addit
pravastatin
therapi
patient
need
mechan
ventil
studi
warrant
interferon
alfa
show
enhanc
antiinfl
uenza
activ
vitro
antivir
addit
immunomodulatori
properti
evid
show
sever
ill
patient
infl
uenza
defi
cient
endogen
interferon
respons
system
interferon
activ
murin
model
viru
infect
macaqu
model
viru
infect
system
combin
system
glucocorticoid
show
possibl
benefi
adequ
toler
treatment
patient
sever
acut
respiratori
syndrom
coronaviru
sar
infect
system
interferon
studi
seriou
infl
uenza
system
glucocorticoid
frequent
use
treatment
infl
uenzaassoci
pneumonia
acut
respiratori
distress
syndrom
ard
includ
hospit
inpati
avian
infl
uenza
ill
almost
patient
given
concurr
antivir
therapi
howev
extens
viral
replic
identifi
ed
patient
season
infl
uenza
given
system
glucocorticoid
manag
chronic
obstruct
pulmonari
diseas
asthma
larg
observ
studi
pandem
report
system
glucocorticoid
administr
pneumonia
ard
associ
increas
secondari
bacteri
fungal
infect
prolong
intens
care
unit
stay
sometim
higher
mortal
intens
care
unit
patient
report
patient
infect
viru
suggest
glucocorticoid
use
might
also
risk
factor
antivir
resist
emerg
consequ
use
infl
uenzaassoci
pneumonia
ard
best
limit
control
clinic
studi
use
ctm
treatment
season
infl
uenza
histori
sever
thousand
year
mechan
ctm
treatment
infl
uenza
complex
incomplet
understood
maxingshigan
one
formul
ctm
directli
inactiv
infl
uenza
viru
idisrupt
adsorpt
protect
cell
becom
infect
administr
chines
herb
might
also
benefi
cial
immunomodulatori
eff
ect
clinic
trial
report
eff
ect
combin
therapi
infl
uenza
one
multicentr
prospect
nonblind
randomis
control
trial
compar
effi
caci
safeti
oseltamivir
maxingshiganyinqiaosan
combin
treatment
outpati
pandem
infl
uenza
primari
search
relev
studi
inclus
done
pubm
jan
may
english
follow
diseas
term
infl
uenza
infl
uenza
human
result
search
cross
drug
term
interferon
oseltamivir
zanamivir
neuraminidas
inhibitor
amantadin
peramivir
rimantadin
ribavirin
vaccin
combin
drug
therapi
combin
combin
drug
therapi
combin
antivir
therapi
antivir
therapi
identifi
ed
abstract
screen
one
research
earlier
studi
also
identifi
ed
fi
le
senior
author
focus
studi
approv
drug
activ
clinic
develop
might
consid
nearterm
clinic
studi
use
combin
articl
studi
investig
drug
progress
develop
eg
invitro
studi
plant
extract
inaccess
languag
barrier
includ
addit
search
three
chines
databas
sinom
former
chines
biomed
literatur
databas
china
knowledg
resourc
integr
databas
wanfang
databas
observ
clinic
studi
control
group
without
laboratoryconfi
rmed
infl
uenza
viru
detect
includ
involv
ctm
appendix
limit
respect
clariti
studi
method
ie
randomis
procedur
blind
placebo
control
adequaci
adverseev
report
mani
potenti
combin
might
consid
studi
variou
criteria
need
thought
select
appropri
intervent
take
forward
clinic
test
tabl
exampl
base
avail
china
present
antivir
combin
oseltamivir
intraven
peramivir
ribavirin
convalesc
plasma
form
neutralis
antibodi
perhap
nitazoxanid
would
candid
test
seriou
infl
uenza
ill
includ
caus
avian
likewis
strategi
clinic
test
need
care
consider
sinc
randomis
control
trial
serious
ill
hospit
inpati
particularli
diffi
cult
resourc
intens
initi
proofofconcept
studi
might
done
altern
popul
experiment
infect
volunt
outpati
infl
uenza
antivir
combin
initi
goal
show
toler
greater
antivir
eff
ect
monotherapi
consequ
smaller
clinic
studi
examin
virolog
endpoint
quantit
virolog
resist
emerg
might
suffi
ce
fi
nd
combin
take
forward
larg
studi
risk
group
hospit
inpati
combin
involv
immunomodulatori
intervent
challeng
great
goal
diseas
amelior
modul
host
respons
unfortun
understand
heterogen
dynam
immun
respons
seriou
human
infl
uenza
relat
diseas
pathogenesi
limit
possibl
use
immunomodulatori
intervent
need
consid
particular
target
popul
diseas
stage
goa
l
either
suppress
advers
host
respons
supplement
defi
cient
one
time
initi
ceas
intervent
relat
cours
ill
adapt
clinic
trial
design
er
greater
fl
exibl
effi
cienci
plan
modifi
cation
chang
sampl
size
treatment
arm
base
statist
analysi
data
gener
earli
stage
trial
incorpor
object
endpoint
design
would
enabl
studi
sever
diff
erent
combin
simultan
fgh
conceiv
review
wrote
fi
rst
draft
jd
review
scientifi
c
literatur
combin
antivir
therapi
develop
associ
appendix
provid
key
revis
text
jkb
review
scientifi
c
literatur
combin
antivir
immunomodulatori
therapi
develop
associ
appendix
provid
key
revis
text
bc
review
scientifi
c
literatur
combin
involv
tradit
chines
medicin
provid
associ
updat
appendic
text
author
contribut
edit
fi
nal
draft
review
author
approv
fi
nal
version
